EXHIBIT 99.1




                                     LUMINEX(R)


                    LUMINEX CORPORATION ANNOUNCES COMPLETION
                          OF RULES-BASED MEDICINE SALE

AUSTIN, Texas, Sept 9 /PRNewsWire-FirstCall/ -- Luminex Corporation (Nasdaq:
LMNX) today announced the completion of the previously announced sale of its
Rules-Based Medicine(TM) research and development project ("RBM") to a newly
formed company headed by Dr. Mark Chandler. RBM uses the Luminex(R) xMAP(TM)
technology to analyze a large number of proteins, metabolites and other
substances in the blood of normal and diseased individuals. In connection with
the sale of RBM, Luminex received both a preferred stock equity interest,
containing a $4.4 million liquidation preference and a 10% nondilutable (prior
to an initial public offering) common stock interest in the newly formed company
that will, independent of Luminex, capitalize and fund the development of RBM.
In connection with this transaction, Luminex and RBM also entered into a
Development and Supply Agreement pursuant to which RBM licensed Luminex's
proprietary xMAP technology. For these rights, Luminex will receive royalties
from the commercialization of RBM's products based on Luminex's xMAP technology,
as well as revenue from the sale of instruments and microspheres.

         As previously announced, Dr. Chandler resigned as Luminex's Chairman,
President and Chief Executive Officer in connection with the closing of the
transaction. Additionally, Dr. Chandler also resigned as a director of Luminex,
effective immediately, in order to focus his efforts on the RBM business. To
provide a smooth transition for the Company, Dr. Chandler will serve as a
consultant to Luminex pursuant to a one-year consulting agreement. In connection
with the resignation of Dr. Chandler, Thomas W. Erickson was elected as Interim
President and Chief Executive Officer to serve in such role until a permanent
replacement for Dr. Chandler is identified. Mr. Erickson provided similar
executive management services as Interim President and Chief Executive Officer
of Omega Healthcare Investors, Inc. (NYSE). In addition, G. Walter Loewenbaum,
Chairman of the Executive Committee of the Board of Directors, was elected
Chairman of the Board of Directors.

About Luminex

         Luminex Corporation develops, manufactures and markets proprietary
biological testing technologies with applications throughout the life sciences
industry. The company's xMAP system is an open-architecture, multi-analyte
technology platform that delivers fast, accurate and cost-effective bioassay
results to markets as diverse as pharmaceutical drug discovery, clinical
diagnostics and biomedical research, including the genomics and proteomics
research markets. The company's xMAP technology is sold worldwide and is already
in use in leading research laboratories as well as major pharmaceutical,
diagnostic and biotechnology companies. Further information on Luminex
Corporation or xMAP can be obtained on the Internet at
http://www.luminexcorp.com.







         Statements made in this press release that express Luminex's or
management's intentions, plans, beliefs, expectations or predictions of future
events are forward-looking statements. The words "believe," "expect," "intend,"
"estimate," "anticipate," "will" and similar expressions are intended to further
identify such forward-looking statements. It is important to note that the
company's actual results or performance could differ materially from those
anticipated or projected in such forward-looking statements. Factors that could
cause Luminex's actual results or performance to differ materially include risks
and uncertainties relating to market demand and acceptance of Luminex's
products, the company's dependence on strategic partners for development,
commercialization and distribution of products, fluctuations in quarterly
results due to a lengthy and unpredictable sales cycle, competition, Luminex's
ability to scale manufacturing operations, potential shortages of components and
the timing of regulatory approvals, as well as the risks discussed under the
heading "Factors That May Affect Future Results" in Luminex's Annual Report on
Form 10-K for the year ended December 31, 2001 and Form 10-Q for the quarter
ended June 30, 2002, as filed with the Securities and Exchange Commission. The
forward-looking statements contained herein represent the judgment of Luminex as
of the date of this press release, and Luminex expressly disclaims any intent,
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements to reflect any change in Luminex's expectations with
regard thereto or any change in events, conditions or circumstances on which any
such statements are based.

Contact:          Harriss T. Currie
                  Luminex Corporation
                  (512) 219-8020